Buscar

Clinical researchers with the Healthy Nevada Project co-author research paper with findings that emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 39 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates have declined progressively due to advancements in treatment and detection. In Nevada there are an estimated 2,310 new breast cancer cases a year, and genetic mutations such as in the genes BRCA1 or BRCA2 remain a top risk factor for this prevalent disease. Recognizing the urgency for progress in breast cancer research, a collaborative effort between physicians, advanced practice providers and scientists from the Healthy Nevada Project® (HNP) and Helix have unveiled groundbreaking research. This study explores how genetic screenings are a necessary supplement to traditional testing methods, together offering more accurate insights into a patient's likelihood of developing breast cancer in the future. HNP is operated by Renown Genomic Medicine and the Institute for Health Innovation and is one of the largest community-based population health studies in the country. Their team works in collaboration with Helix, a leader in precision health that delivers comprehensive genomic solutions. Together, this dynamic partnership aims to understand breast cancer risk factors and pave the way for more effective preventative measures. The combined research team studied 25,591 female HNP participants to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer. The results of this research suggest that a combined monogenic, or single-gene, and polygenic, or multi-gene, approach to breast cancer screenings helped produce more accurate results and more closely identify study participants who have a high genetic risk of developing the disease. "Based on this research, we are advocating a shift in approach which would improve breast cancer risk assessment through a combination of effective family history ascertainment and genetic screening,” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project, research professor at the University of Nevada, Reno School of Medicine and co-author of the breast cancer research paper. “This tailored approach, founded on the assessment of individual genetic risk, not only intends to elevate patient well-being but also will improve efficiency and equity in healthcare." Complementing the team’s research on leveraging genetics to identify women at low genetic risk of breast cancer that could safely defer mammogram screenings by five to 10 years that was released in late 2023 in JAMA Oncology, the study suggests that incorporating genetic information can assist in personalizing breast cancer screenings and optimizing the use of screening resources. "Existing disparities persist across various facets of breast cancer screening and treatment; however, genetic screening is clearly a powerful tool to help facilitate early intervention for those at higher risk,” said Jamie Schnell Blitstein, APRN, a primary care nurse practitioner at Renown Health and co-author of the breast cancer research paper. “By placing a heightened focus on risk, we underscore the pivotal role of preventative breast cancer screening.” Despite the availability of effective methods for early screening, co-authors of this research found that 78 percent of women with a family history of breast cancer had their risk ascertained only after a breast cancer diagnosis. The findings emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  “These findings that can profoundly impact how healthcare is delivered were only made possible by all the participants who were willing to consent to research,” said Alex Bolze, PhD from Helix and co-author of the publication. “Broad-scale collaboration projects like these between Renown Health and UNR that engage large populations where participants share both their genetic information as well as electronic health records drive advancements in preventative medicine, as well as fundamental biological research.”   The research paper was officially accepted on Jan. 29, 2024, and will be published by Elsevier, Inc. on behalf of the American College of Medical Genetics and Genomics. The contents of the paper will appear in the international journal Genetics in Medicine Open. Read the full article by visiting sciencedirect.com. The Healthy Nevada Project is currently recruiting new study participants. Free to all Nevadans with a saliva sample or blood draw, participants and their referring providers receive access to whole-exome sequencing and clinical grade results that help provide insight into their unique genetic risks tied to heart disease and certain cancers. If you are interested in enrolling in the study, schedule a Virtual Consent Appointment through MyChart or contact the Renown Institute for Health Innovation at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About Renown Health Renown Health is the region’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown is currently enrolling participants in the largest community-based genetic population health study, the Healthy Nevada Project®. To join the Renown Health team, visit renown.org/careers. Acerca de Helix Helix es la compañía líder en genómica y vigilancia viral de la población cuyas operaciones se basan en el cuidado clínico, la investigación y el análisis de datos. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision-making. Learn more at helix.com.

Leer más About Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results

Two pediatric gastroenterologists bring life-saving care to kids and make Renown their new home The Renown Children’s Hospital team and our community is celebrating the addition of a new life-saving pediatric specialty to its practice serving children and families in northern Nevada. Parents and guardians will now be able to seek professional pediatric gastroenterologist care with the addition of Drs. Juan Gregory and Kathleen Holland to Renown Medical Group. “Recognizing the importance of diagnosing and caring for children who have conditions that affect the organs in the digestive system, including the stomach, liver and bowel, while also helping children who have issues feeding and eating, is critically important to us at Renown,” said Kristina Deeter, MD, MBA, FAAP, Chair of Pediatrics, University of Nevada Reno School of Medicine (UNR Med) and Physician-in-Chief, Renown Children’s Hospital. “Both Drs. Gregory and Holland are superb clinicians, we are excited to have them join Renown Children’s Hospital to offer pediatric gastroenterology services, including a wide range of complex and vital procedures and screenings, endoscopies and colonoscopies.” Juan Carlos Gregory, MD, has 18 years of experience caring for children in northern Nevada. He is a clinical associate professor of pediatrics at UNR Med with a special interest in celiac disease, abdominal pain, and gastroesophageal reflux in children. Gregory earned his undergraduate degree at Texas Christian University in Fort Worth, TX before completing his medical training, including a residency in pediatrics at the University of San Diego in Pediatrics and fellowships in Pediatric Gastroenterology and Nutrition at both Children’s National Medical Center in Washington, DC, and at the National Institutes of Health, Digestive Disease Section in Bethesda, MD. He is board-certified in Pediatric Gastroenterology and speaks Spanish. Kathleen Holland, MD, MPH brings a global health perspective to her work caring for children. A graduate of the University of Nevada Reno School of Medicine (UNR Med) with her medical doctorate and her master’s in public health with a social and behavioral health emphasis, she has donated her skills to providing international medical relief for children in Uganda and Nicaragua. Holland earned her undergraduate degree at University of Nevada Reno in Biology, Health Ecology and Healthcare Ethics before completing her medical training and residency in Pediatrics and a fellowship in Pediatric Gastroenterology at Indiana University School of Medicine in Indianapolis, IN. Her research and scientific interests include vaccination rates and family barriers among children with inflammatory bowel disease, Crohn’s and colitis, pediatric autoimmune pancreatitis, and cystic fibrosis. How Pediatric Gastroenterologists Help Children and Families The Pediatric Gastroenterology Program at Renown Children’s cares for children experiencing common GI-related problems of childhood; nausea, vomiting, abdominal pain, diarrhea, constipation, reflux, colic, milk protein allergy, poor growth and feeding difficulties, and sees patients from infancy to 18 years old. “As specialists in the care of children with gastrointestinal and liver problems, we focus on the diagnosis and treatment of these issues,” said Larry Duncan, MD, Vice President of Pediatrics and Surgery & Administrator of Renown Children’s & Women’s Services. “Our physicians play an active role in teaching and research. We have several areas of expertise including prevention, diagnosis and treating disease of the digestive tract including the esophagus, gallbladder, stomach, pancreas, colon, small intestine and liver disease.” Special expertise includes: Pediatric feeding and growing disorders Aerodigestive disorders Food and hypersensitivity disorders Inflammatory bowel disease Celiac disease Liver diseases Children requiring parenteral and enteral nutrition Renown Children’s Hospital is the only dedicated children’s hospital in northern Nevada, offering programs and services for families from a 100,000 square mile area, from Sacramento, CA to Salt Lake City, Utah. Renown Children’s provides the area’s only Children’s Emergency Room, Pediatric ICU (PICU), children’s imaging center and the largest neonatal ICU (NICU), a level III intensive care unit. Specialty Children’s Care at Renown Today, over 90% of families in northern Nevada seek care from the experts at Renown Children’s Hospital. “We are so grateful to the William N. Pennington Foundation for its support in establishing the William N. Pennington Fund for Advance Pediatric Care in 2016, which allowed us to hire our first 15 pediatric specialists,” said Dr. Deeter. “Today we have over 40 pediatric physician specialists at Renown Children’s Hospital who provide care in adolescent medicine, pediatric endocrinology, pediatric hematology/oncology, pediatric pulmonology, pediatric neurology, pediatric nephrology, pediatric infectious diseases, pediatric ophthalmology, pediatric orthopedic surgery, pediatric cleft and craniofacial surgery, pediatric urology, pediatric dentistry, pediatric emergency medicine, and now, pediatric gastroenterology. Our clinicians provide 30,000 patient visits annually, offering an exceptional level of care. The Pennington gift is truly a gift that keeps giving to the families in our area.” Now Being Constructed: Expanded Inpatient Care at Renown Children’s Hospital New construction of an expanded Neonatal Intensive Care Unit (NICU) with increased capacity to 49 bassinets, an expanded Pediatric Intensive Care Unit (PICU) with increased capacity to 16 private patient and family rooms, and a new Renown Children's Hospital inpatient floor with increased capacity for 38 private patient and family rooms for a total capacity of 58 pediatric beds are currently being constructed on Tahoe Tower, Level 5 of Renown Regional Medical Center. It is expected that the new units will open to patients and families in April 2023. In the most recent US News & World Report Best Hospital rankings, Renown Regional Medical Center was named as the number one hospital in Nevada. Ningún otro hospital del estado cumplió con sus estrictos estándares para el ranking de 2021. Renown Health is High Performing, its highest rating possible, in eight procedures and conditions including Heart Failure, Colon Cancer Surgery and Chronic Obstructive Pulmonary Disease, Hip Replacement and Knee Replacement. A hospital's score is based on multiple data categories, including patient outcomes, safety, and volumes. Los hospitales calificados como sobresalientes eran significativamente mejores que el promedio nacional. Renown Medical Group is an in-network provider for Hometown Health and other health plans. Drs. Gregory and Holland are pleased to see new patients at their location at the Renown Children’s Subspecialty Clinic inside Renown Regional Medical Center at 75 Pringle Way, Suite 505, Reno, Nev. Ask your pediatrician for a referral to a medical specialist when further evaluation of a particular issue is necessary. About Renown Health Renown Health is Nevada’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in a community-based genetic population health study, the Healthy Nevada Project®.  About UNR Med The University of Nevada, Reno School of Medicine (UNR Med), Nevada’s first public medical school, is a community-based, research-intensive medical school with a statewide vision for a healthy Nevada. Since 1969, UNR Med has trained more than 3,900 students, residents, and fellows. UNR Med continues to improve the health and well-being of all Nevadans and their communities through excellence in student education, postgraduate training and clinical care, research with local, national and global impact and a culture of diversity and inclusion. For more information, visit med.unr.edu.

Leer más About Tummy Trouble? Renown Children’s Hospital Adds Another New Specialty, Pediatric Gastroenterology

Renown Children’s Hospital pediatric ophthalmologist Dr. Mitchell Strominger hosts state-wide virtual event to provide routine vison screenings for children and Walk with a Doc. El Dr. Mitchell Strominger, oftalmólogo pediátrico del Renown Children’s Hospital, organizará el evento virtual “Walk with a Doc” (Recorrido con un médico) el domingo, 14 de junio a las 10 a.m. para niños de escuela primaria y sus padres. During this free event, Dr. Strominger will give a brief, kid-friendly talk about the importance of routine vision screenings and show parents how to conduct a vision screening with their kids at home. He will close out the morning session with a live Q&A. Following the event, families are encouraged to get outside and enjoy a walk in the great outdoors. The event is sponsored by Renown Children’s Hospital and free to participants, however you must register to receive the link to attend. “Vision is important for learning, experiencing new things and interacting with others, which is why it’s critical for children to get vision screenings early and routinely,” said Dr. Strominger. “The best time to screen a child’s vision is kindergarten through third grade as the cells in the brain responsible for vision are continuously developing up until age eight. If we detect vision problems early, we here at Renown Children’s Hospital have the expertise and technology to correct these vision problems and enable children to live healthy, productive lives.” Individuals who register for this event will be emailed a vision-screening sheet to help facilitate an at-home screening, as well as a form to send back to their child’s pediatrician or pediatric ophthalmologist upon completion to determine the best course of action. El Dr. Strominger agregó: “Muchos padres y colegios han pospuesto los exámenes de la visión debido al cierre de los colegios por la COVID-19, a las dudas respecto de la seguridad al salir de casa o a los posibles costos financieros. I am pleased to host this virtual event on behalf of Renown Children’s Hospital, to engage kids and parents in a conversation on the importance of vision and to remind the community that we are here to help and provide the care they need, both in-person and virtually—be it over a smart phone, tablet or computer screen.” Este evento virtual se llevará a cabo en el recién renovado Fianna’s Healing Garden, que reabrirá sus puertas a finales de este mes y el 100 % de su renovación se financió con donaciones a través de la fundación de Renown Health. Located in the heart of Renown Regional Medical Center, the healing garden serves as place to enjoy the serenity and beauty of the outdoors. El Dr. Strominger es uno de los 26 subespecialistas pediátricos reclutados en Renown Children’s Hospital desde 2016, gracias a la donación de $7.5 millones que Pennington Foundation realizó a la fundación de Renown Health sin fines de lucro para expandir los servicios de salud de los niños. June marks the four-year anniversary of the Nevada Chapter of the American Academy of Pediatrics’ (Nevada APP) participation in the national Walk with A Doc event. Dr. Strominger is the secretary and treasurer for the Nevada AAP. El Renown Children’s Hospital se dedica a ayudar a los niños a sentirse bienvenidos, seguros y bien atendidos. Este centro abarca desde especialidades pediátricas, atención en la sala de emergencias y cirugía las 24 horas, los 7 días de la semana, hasta el diagnóstico por imágenes, la unidad de cuidados intensivos (UCI) pediátrica y los especialistas en vida infantil. Through each visit, parents can expect the highest level of care for their child’s health and well-being from birth and beyond. To support Renown Children’s Hospital and help local children in need get access to vital health services like routine vision screenings, please visit the Renown Health Foundation.     About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. Renown es uno de los mayores empleadores privados de la región y cuenta con una fuerza laboral de más de 7,000. It comprises three acute care hospitals, Renown Children’s Hospital, Renown Rehabilitation Hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown has a long tradition and commitment to continually improve the care and the health of our community. Visite renown.org para obtener más información.

Leer más About Elementary Schoolers: Take Part in Free Virtual Vision Screening

Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. En virtud de los términos del acuerdo de colaboración y licencia, Gilead proporcionará fondos al Renown IHI para secuenciar y analizar el ADN de 15,000 personas que viven con EHNA o con enfermedad de hígado graso no alcohólico (EHGNA), así como de una cohorte de control de 40,000 personas en el estado de Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health es la red de atención médica más completa e integrada de Nevada y mantiene registros médicos electrónicos para 1.02 millones de pacientes registrados. En 2016, Renown Health y el Desert Research Institute crearon el Healthy Nevada Project (HNP), el primer estudio de salud poblacional basado en la comunidad del país. En 2017, el HNP comenzó una sociedad con Helix para aprovechar sus servicios de salud poblacional, la secuenciación Exome+™ y las herramientas de participación del consumidor. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. El HNP actualmente tiene 40,000 participantes. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.”     About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. La EHNA es más frecuente en personas con ciertas afecciones, que incluyen obesidad y diabetes tipo 2. There are currently limited approved treatments for patients living with NASH.   About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead opera en más de 35 países alrededor del mundo, con sede central en Foster City, California. Para obtener más información sobre Gilead Sciences, visite el sitio web de la empresa en www.gilead.com.   About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown es uno de los mayores empleadores privados de la región y cuenta con una fuerza laboral de más de 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org.    About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Mediante el uso de su ensayo Exome+™ de propiedad exclusiva, un exoma de tipo panel mejorado con más de 300,000 regiones no codificantes informativas, Helix ofrece a los sistemas de salud una solución escalable que permite el descubrimiento de información genética médicamente relevante y que potencialmente puede salvar vidas. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Obtenga más información en www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC.   Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Estos y otros riesgos se describen en detalle en el Informe Trimestral de Gilead en el Formulario 10-Q para el trimestre que finalizó el 31 de marzo de 2019, presentado ante la Comisión de Bolsa y Valores de los EE. UU. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.   Additional Media Contact: Sung Lee, Investors                                                                                                                                                        650-524-7792 Arran Attridge, Media                                                                                                                                                        650-425-8975

Leer más About Gilead Sciences y el Renown Institute for Health Innovation anuncian una colaboración estratégica para promover la comprensión de la esteatohepatitis no alcohólica (EHNA)